Peripheral T-lymphocyte subpopulations in different clinical stages of chronic HBV infection correlate with HBV load

Table 3 Peripheral T-cell subsets broken down by various factors in normal controls and chronic HBV infection patients (mean ± SD)

Groups	Patients (n)	CD3+	CD4+	CD8+	CD4+/CD8+ ratio
HBV statusb
Negative (normal control)	100	71.07 ± 4.76	38.94 ± 3.39	24.02 ± 4.35	1.67 ± 0.33
Positive	422	56.42 ± 13.16	31.97 ± 7.30	33.73 ± 8.63	1.04 ± 0.45
Clinical stages of HBV infectionc
Tolerant	112	50.78 ± 13.26	30.23 ± 6.35	36.87 ± 7.58	0.86 ± 0.29
Active	222	55.51 ± 12.50	30.92 ± 7.40	34.37 ± 9.07	1.00 ± 0.47
Inactive carrier	88	65.89 ± 9.09	36.85 ± 6.06	28.09 ± 5.64	1.37 ± 0.39
HBV DNA loads (copies/mL)d
≤ 1.0 × 103	137	65.96 ± 8.58	37.45 ± 6.14	26.89 ± 5.71	1.46 ± 0.42
> 1.0 × 103-1.0 × 105	46	62.28 ± 7.50	33.33 ± 5.61	31.81 ± 5.95	1.10 ± 0.36
> 1.0 × 105-1.0 × 107	60	60.05 ± 12.97	31.58 ± 6.99	33.83 ± 7.50	0.97 ± 0.26
> 1.0 × 107	179	46.39 ± 9.93	27.56 ± 5.49	39.41 ± 7.36	0.73 ± 0.23
HBeAg statusb
Negative	204	62.62 ± 10.67	34.83 ± 7.16	29.66 ± 7.35	1.27 ± 0.48
Positive	218	50.61 ± 12.62	29.29 ± 6.37	37.53 ± 7.98	0.83 ± 0.29
HBV pre-C region mutation statusb
Negative	300	58.40 ± 12.89	33.63 ± 6.94	31.73 ± 8.04	1.15 ± 0.44
Positive	122	51.55 ± 12.57	27.89 ± 6.56	38.63 ± 8.06	0.78 ± 0.37
Maternal HBV-infection statusb
Negative	189	62.34 ± 10.89	35.31 ± 6.32	29.64 ± 6.87	1.27 ± 0.43
Positive	233	51.61 ± 12.89	29.27 ± 6.93	37.04 ± 8.49	0.85 ± 0.37
Age at HBV infectionc (yr)
< 8	166	51.83 ± 12.86	28.17 ± 6.61	37.31 ± 8.16	0.80 ± 0.29
8-20	127	57.17 ± 12.27	33.05 ± 5.90	33.39 ± 7.91	1.07 ± 0.41
> 20	103	61.42 ± 11.89	36.02 ± 7.27	28.86 ± 7.89	1.35 ± 0.49
Unknown	26	62.25 ± 14.39	34.93 ± 6.34	31.78 ± 7.58	1.19 ± 0.45

Effects of various independent demographic, clinical and serological variables on T-cell profile of HBsAg positive individuals were analyzed.

^bP < 0.001 vs measurement of each T-cell parameter;

^cP < 0.01,

^dP < 0.001 vs ANOVA linear trend test.